Synchron Closes $310M Series E to Accelerate Stentrode BCI Commercialization

Synchron has secured $310 million in a Series E funding round, the company announced this morning, marking one of the largest single financing events in brain-computer interface history and signaling continued institutional confidence in the endovascular BCI approach. The round was co-led by Khosla Ventures and Wellington Management, with participation from existing backers including ARCH Venture Partners, Bezos Expeditions, and a consortium of strategic health system investors.

Capital Deployment and Clinical Expansion

The New York-based company will deploy the capital across three primary areas: scaling manufacturing capacity for its Stentrode device, expanding the clinical operations infrastructure required for a pivotal FDA trial expected to begin enrollment in Q1 2027, and broadening its software ecosystem to support a wider range of motor and communication applications for patients with paralysis and ALS.

Synchron's Stentrode distinguishes itself from competing BCI platforms by being implanted via a minimally invasive endovascular procedure rather than open-brain surgery. The device is threaded through the jugular vein and positioned in the superior sagittal sinus adjacent to the motor cortex, where it records neural signals without penetrating brain tissue. The company reported last month that its Australian and U.S. early feasibility study participants have now logged a cumulative total exceeding 400,000 hours of device use, with no serious adverse device-related events reported across the cohort.

Regulatory Readiness and Market Competition

CEO Tom Oxley framed the raise in terms of the competitive window the company currently occupies. "We are at the point where clinical evidence, regulatory dialogue, and manufacturing readiness are converging," Oxley said in a statement. "This capital lets us execute on all three simultaneously rather than sequentially." The company confirmed it has been in regular pre-submission meetings with the FDA's Center for Devices and Radiological Health throughout 2025 and 2026.

The funding round arrives as the broader BCI sector navigates an increasingly complex regulatory and commercial environment. Neuralink's ongoing PRIME study continues to generate both scientific interest and public scrutiny, while Precision Neuroscience has pushed further into its cortical array roadmap following a partnership with a major academic medical center announced earlier this quarter. Investors appear to be placing differentiated bets across surgical modalities rather than consolidating behind a single platform approach.

Synchron's Series E brings its total disclosed funding to approximately $590 million. The company employs roughly 280 staff across its New York headquarters, Melbourne R&D operations, and a newly opened Fremont, California manufacturing facility.